Pharmaceutical industry leaders are advocating for stability and predictability from the next Food and Drug Administration (FDA) commissioner following a period of leadership changes and uncertainty. CEOs from major drug companies emphasized the need for consistent regulatory rules, given the long development timelines and significant investments involved in bringing new medicines to market. The industry also expressed concerns about potential drug pricing policies, such as "most favored nation" pricing, fearing it could lead to rationing of care. AI
排序理由 Article discusses industry opinions and concerns regarding potential regulatory and policy changes, rather than a specific event.
AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →
